Physician profile
Scott J Meyer
NPI 1417935057
$7,257.87
in general payments reported to CMS, 2019-2025
41 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,261 · 2020: $1,762 · 2021: $2,168 · 2022: $1,067.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,057.86 | 2019-2022 | |
| Abbvie INC. | $931.77 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $611.54 | 2019-2022 | |
| Allergan, INC. | $502.12 | 2019-2020 | |
| Amgen INC. | $403.40 | 2019-2022 | |
| Lilly USA, LLC | $352.86 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $349.62 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $307.42 | 2019-2022 | |
| Amarin Pharma, INC. | $270.99 | 2019-2021 | |
| Amneal Pharmaceuticals LLC | $249.65 | 2019-2022 | |
| Currax Pharmaceuticals LLC | $222.42 | 2020-2021 | |
| Pfizer INC. | $208.79 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $202.57 | 2019-2021 | |
| Horizon Therapeutics Plc | $189.77 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $185.39 | 2019-2021 |
Show all 41 companies
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Meyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.